- Dance 501, a liquid formulation of human insulin for inhalation (INH) with the aerosol Dance 501 inhaler device, was associated with a more rapid onset of action compared with subcutaneous insulin lispro in patients with type 2 diabetes (T2D).
Why this matters
- Subcutaneous injections of insulin can be burdensome for some patients with diabetes.
- INH was associated with a faster onset of action than insulin lispro (median differences 6.5-20 minutes; P<.02>
- The INH group also experienced greater action in the first hour following treatment (median relative differences, 45%-107%; P<.05>
- Both INH and insulin lispro showed a linear dose-response relationship as well as comparable total pharmacodynamic action (P>.2 for AUC_GIR0-10 hour comparison at each dose level).
- Median relative biopotency of INH was between 12.2% and 13.0%.
- No safety issues were associated with inhalation.
- A total of 24 patients with T2D (mean±standard deviation age, 61.8±7.9 years; BMI, 30.4±2.6 kg/m2) who were taking daily insulin therapy were randomly assigned to either subcutaneous insulin lispro injections (n=12) or INH (n=12).
- Doses of insulin lispro were low (12 U), medium (24 U), and high (48 U), and INH was inhaled at equivalent doses.
- Funding: Dance Biopharm Inc.
- Small sample size.